Skip to main content
Livermore
Livermore
ZHEN

Nautilus Biotechnology, Inc.

NAUT
Exchange
Nasdaq
Industry
Laboratory Analytical Instruments
SEC CIK
0001808805

No open-market purchases or sales by Nautilus Biotechnology, Inc. insiders were filed in the last 90 days; 93 institutions reported holding it in 13F filings for Q2 2026, worth $93.7M in total; no superinvestor holds it.

Holders of 5% or more of NAUT

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Nautilus Biotechnology, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of NAUT
HolderLatest formStakeChangeFirst filedLatest filingFiling
Mallick Parag13D/A17.40%22.3M shares–Mar 5, 20251 filingMar 5, 2025SEC
Patel Sujal M13D/A15.70%20.3M shares–Mar 5, 20251 filingMar 5, 2025SEC
Perceptive Advisors LLC13D/A10.10%12.8M shares+0.10 ppfrom 10.00%Jan 31, 20252 filingsJun 24, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

4 Schedule 13D and 13G filings on Nautilus Biotechnology, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on NAUT
Filed (ET)FilerFormStakeChangeEvent dateFiling
Jun 24, 20254:42 PM ETPerceptive Advisors LLCand 2 others13D/A10.10%12.8M shares+0.10 ppfrom 10.00%Jun 20, 2025SEC
Mar 5, 20254:57 PM ETMallick Parag13D/A17.40%22.3M shares–Mar 3, 2025SEC
Mar 5, 20254:54 PM ETPatel Sujal M13D/A15.70%20.3M shares–Mar 3, 2025SEC
Jan 31, 20259:06 PM ETPerceptive Advisors LLCand 2 others13D/A10.00%12.6M shares–Jan 31, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Nautilus Biotechnology, Inc. shares.

No Form 144 notices for Nautilus Biotechnology, Inc. are on file.